- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04115956
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy. Melflufen will be administered on Day 1 of each 28-day cycle in combination with dexamethasone on days 1 and 2.
In both phases, treatment of each individual participant will continue for up to 8 cycles or until any stopping events occur.
Approximately 46 participants will be enrolled.
The study was intended to be a Phase 1/2 trial but was early terminated and never moved forward to Phase 2.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a clinical trial of melphalan flufenamide (melflufen), a peptide-conjugated alkylator which belongs to an novel class of drugs called peptidase-enhanced compounds, and targets the transformation process of tumor cells with a unique mechanism of action, as potential treatment option of AL amyloidosis.
AL amyloidosis is a rare progressive disease caused by proteotoxic light chain protein produced by small plasma cell clone. This plasma cell dyscrasia is characterized by monoclonal plasma cell's excessive production of monoclonal immunoglobulin light-chains that tends to misfold and subsequently deposit as amyloid fibrils in visceral organs. The plasma cell dyscrasia in AL amyloidosis is similar to that in multiple myeloma (MM) and therapies that are effective in MM are often used to treat AL amyloidosis.
Melphalan flufenamide is currently been evaluated in several ongoing clinical trials in patients with multiple myeloma, with observed efficacy. There are currently no therapies approved for treatment of AL amyloidosis and based on the efficacy of melphalan flufenamide and the demonstrated efficacy of melphalan (and other alkylators), it is anticipated that patients with AL amyloidosis may receive benefit from treatment with melphalan flufenamide.
This study consist of a screening period (up to 28 days), a treatment period (up to 8 cycles) and a follow-up period (up to 24 months).
Phase 1: Approximately 8-30 participants will be screened to achieve 7-23 enrolled participants.
Phase 2: Approximately 30 participants will be screened to achieve 23 enrolled participants.
The study was intended to be a Phase 1/2 trial but was early terminated and study never moved forward to Phase 2.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Ostrava - Poruba, Czechia, 70852
- Fakultni nemocnice Ostrava
-
-
-
-
-
Limoges, France, 87000
- Centre Hospitalier Universitaire de Limoges
-
-
-
-
-
Heidelberg, Germany, 69120
- Universitätsklinikum Heidelberg
-
-
-
-
-
Athen, Greece, 11528
- Alexandra General Hospital of Athens
-
-
-
-
-
Jerusalem, Israel, 9112001
- Hadassah University Hospital Ein Kerem
-
-
-
-
-
Oslo, Norway, 0372
- Oslo University Hospital - Rikshospitalet
-
-
-
-
-
Barcelona, Spain, 08036
- Hospital Clinic De Barcelona
-
-
-
-
-
London, United Kingdom, NW1 2BU
- University College London Hospitals NHS Foundation Trust
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Boston University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: (For full list of inclusion criteria, see study protocol)
- Male or female, age 18 years or older at the time of signing the informed consent
- Proven histochemical diagnosis of AL amyloidosis based on tissue specimens with Congo red staining
- At least one prior line of therapy, defined as either one non-transplant regimen, one ASCT (autologous stem cell transplantation), or one regimen of induction therapy followed by a single ASCT. No more that 4 cycles of melphalan containing chemotherapy is allowed.
- Measurable hematologic disease
- Objectively measurable organ amyloid involvement
- ECOG performance status ≤ 2 (ECOG = Eastern cooperative oncology group)
- Women of child bearing potential must have a negative serum or urine pregnancy test
- Less than 30% plasma cells in bone marrow aspirate or biopsy
- Acceptable laboratory results met (absolute neutrophil count (ANC), platelet count, hemoglobin, total bilirubin,alkaline phosphatase, AST (aspartate aminotransferase) and ALT (alanine aminotransferase), renal function)
- Male participant agrees to use contraception during treatment and 90 days after last dose of melflufen
Exclusion Criteria: (For full list of exclusion criteria, see study protocol)
- Amyloidosis due to known mutations of the transthyretin gene or presence of another non-AL amyloidosis
- Evidence of gastro-intestinal bleeding
- Cardiac risk stage 3
- Low platelets value with evidence of mucosal or internal bleeding
- Medical documented cardiac syncope, NYHA Class 3 or 4 congestive heart failure, myocardial infarction, unstable angina pectoris, clinically significant ventricular arrhythmias (NYHA=New York Heart Association Functional Classification)
- Clinically significant finding on 24 h Holter recording
- Severe orthostatic hypotension
- Clinically significant factor X deficiency
- Clinically significant autonomic disease
- Any medical condition that would impose excessive risk to the patient
- Serious psychiatric illness, active alcoholism or drug addiction that may hinder or confuse compliance
- Known HIV or active hepatitis B or C viral infections
- Previous cytotoxic therapies, including cytotoxic investigational agents within 3 weeks prior to start of study treatment. Monoclonal antibodies within 4 weeks. Concomitant immunotherapy, investigational therapy and anticoagulation therapy are not permitted
- Prior autologous or allogenic stem cell transplant within 12 weeks of initiation of therapy
- Prior allogeneic stem cell transplant with active graft-host-disease
- Prior major surgical procedure or radiation therapy within 4 weeks of the first dose of study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Melflufen and dexamethasone in combination
Intravenous infusion of melflufen Day 1 of 28 day cycles, in combination of dexamethasone on Days 1 and 2 of each 28-day cycle.
|
Treatment consist of i.v.
melflufen on Day 1 of each 28-day cycle.
Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary objective in Phase 1 is to explore safety and tolerability of melflufen
Time Frame: During phase 1 for up to 8 cycles of treatment of 28 days each (approx. up to 8 months)
|
Endpoints:
|
During phase 1 for up to 8 cycles of treatment of 28 days each (approx. up to 8 months)
|
The primary objective in Phase 1 is to identify recommended Phase 2 dose (RP2D)
Time Frame: During phase 1 for up to 8 cycles of 28 days each (approx. up to 8 months)
|
Endpoint: Dose-Limiting Toxicity (DLT) during Cycle 1 up to maximum dose of melflufen of 40 mg.
A DLT event is defined as thrombocytopenia, neutropenia, non-hematologic toxicity and/or inability to receive Cycle 2 Day 1 dose within 14 days from planned Cycle 2 Day 2 due to continued melflufen-related toxicity from Cycle 1.
|
During phase 1 for up to 8 cycles of 28 days each (approx. up to 8 months)
|
The primary endpoint in Phase 2 is to evaluate the hematologic overall response rate (ORR) after 4 cycles at the RP2D determined in Phase 1
Time Frame: During phase 2 after 4 cycles of treatment ( approx. 4 months)
|
The proportion of participants who achieve a hematologic Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR)
|
During phase 2 after 4 cycles of treatment ( approx. 4 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess pharmacokinetic profile of melflufen in this patient population
Time Frame: At Cycle 1 Day 1 and Cycle 2 Day 1 at time points 5-10 minutes, 1-2 hours and 3-8 hours after end of infusion. Each cycle length is 28 days.
|
Melphalan plasma concentration post melflufen administration at 3 time points
|
At Cycle 1 Day 1 and Cycle 2 Day 1 at time points 5-10 minutes, 1-2 hours and 3-8 hours after end of infusion. Each cycle length is 28 days.
|
To assess best hematologic response
Time Frame: Throughout the study treatment of up to 8 cycles of 28 days each (approx. 8 months) per patient
|
Proportion of patients with each outcome (Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR), No Response (NR) or Progressive Disease (PD))
|
Throughout the study treatment of up to 8 cycles of 28 days each (approx. 8 months) per patient
|
To assess the duration of hematologic response
Time Frame: Throughout the study treatment period of up to 8 cycles of 28 days each (approx 8 months) per patient
|
Median time (Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR), No Response (NR) or Progressive Disease (PD))
|
Throughout the study treatment period of up to 8 cycles of 28 days each (approx 8 months) per patient
|
To assess the proportion of organ system responses
Time Frame: Throughout the study treatment period of up to 8 cycles of 28 days each (approx 8 months) per patient
|
Proportion of participants with kidney, cardiac or liver response, respectively
|
Throughout the study treatment period of up to 8 cycles of 28 days each (approx 8 months) per patient
|
To assess duration of organ system responses
Time Frame: Throughout the study treatment period of up to 8 cycles (approx 8 months) per patient
|
Duration of organ responses separately for each organ
|
Throughout the study treatment period of up to 8 cycles (approx 8 months) per patient
|
To assess hematologic ORR (overall response rate)
Time Frame: During phase 1 for up to 8 cycles of treatment of 28 days each (approx. up to 8 months)
|
Proportion of participants who achieve a hematologic CR, VGPR or PR
|
During phase 1 for up to 8 cycles of treatment of 28 days each (approx. up to 8 months)
|
To assess time to next AL amyloidosis treatment
Time Frame: Throughout the study, covering up to 8 cycles (approx. 8 months) of treatment and 24 months of follow up
|
Time to next AL amyloidosis treatment
|
Throughout the study, covering up to 8 cycles (approx. 8 months) of treatment and 24 months of follow up
|
To assess Overall Survival (OS)
Time Frame: Throughout the study, covering up to 8 cycles (approx. 8 months) of treatment and up to 24 months of follow up
|
Overall survival
|
Throughout the study, covering up to 8 cycles (approx. 8 months) of treatment and up to 24 months of follow up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Giovanni Palladini, MD, University Hospital San Matteo in Pavia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Paraproteinemias
- Proteostasis Deficiencies
- Neoplasms, Plasma Cell
- Immunoglobulin Light-chain Amyloidosis
- Amyloidosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Dexamethasone
- Melphalan
Other Study ID Numbers
- OP201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AL Amyloidosis
-
Nexcella Inc.Not yet recruitingLight Chain (AL) AmyloidosisUnited States
-
Peking Union Medical College HospitalRecruitingLight Chain (AL) Amyloidosis | Venetoclax | CCND1 TranslocationChina
-
Sorrento Therapeutics, Inc.WithdrawnLight Chain (AL) Amyloidosis
-
Boston Medical CenterMillennium Pharmaceuticals, Inc.Completed
-
European Myeloma NetworkJanssen PharmaceuticaActive, not recruitingLight Chain (AL) Amyloidosis, Stage 3BNetherlands, Greece, France, Italy
-
Tufts Medical CenterSanofiWithdrawnAmyloidosis | Light Chain (AL) Amyloidosis
-
Sorrento Therapeutics, Inc.RecruitingLight Chain (AL) AmyloidosisUnited States
-
Weill Medical College of Cornell UniversityJanssen Scientific Affairs, LLCRecruitingAL Amyloidosis | Amyloid | Refractory AL AmyloidosisUnited States
-
IRCCS Policlinico S. MatteoTerminatedCardiac AL AmyloidosisSpain, France, Italy, Germany, Canada, Greece, Turkey, United Kingdom
-
Florian MichelGerman Federal Ministry of Education and ResearchCompletedLight Chain (AL) Amyloidosis | Cardiac InvolvementGermany
Clinical Trials on Melphalan-Flufenamide (Melflufen)
-
Oncopeptides ABTerminatedMultiple Myeloma | Renal ImpairmentGreece, Czechia, Poland
-
Oncopeptides ABPrecision For MedicineCompletedMultiple MyelomaSpain, United States, France, Italy
-
Oncopeptides ABApproved for marketingRelapsed and/or Refractory Multiple MyelomaUnited States
-
Oncopeptides ABTerminatedRRMMBulgaria, United States, Czechia, Hungary, Ukraine
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Oncopeptides ABTerminatedMultiple MyelomaUnited States, France, Spain, Czechia
-
Oncopeptides ABTerminatedMultiple MyelomaUnited States, Austria, Belgium, Czechia, Denmark, Estonia, France, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom
-
Hadassah Medical OrganizationUnknown
-
Uppsala UniversityDalarna County Council, Sweden; Uppsala County Council, SwedenNot yet recruitingMyeloma Multiple
-
University of California, San FranciscoTerminatedMultiple Myeloma | Patient ParticipationUnited States